Table 2.
Clinical trials targeting or potentially targeting histone modifications in ALL.
| NCT Number |
Phase | Epigenetic Therapy |
Target | ALL Conditions |
Start Year | Status |
|---|---|---|---|---|---|---|
| NCT00053963 | I | FR901228 | Histone deacetylases | Refractory (0–21 years) | 2002 | Completed |
| NCT00217412 | I | Vorinostat | Histone deacetylases | Relapsed or refractory (1–21 years) | 2005 | Completed |
| NCT00882206 | II | Vorinostat | Histone deacetylases | Relapsed or refractory (2–60 years) | 2009 | Completed |
| NCT01251965 | I/II | Ruxolitinib | JAK1/JAK2 kinases | Relapsed or refractory (14 years, or older) | 2010 | Completed |
| NCT01321346 | I | Panobinostat | Histone deacetylases | Refractory (8–21 years) | 2011 | Completed |
| NCT02141828 | I | EPZ-5676 | H3K79 methyltransferases | Relapsed or refractory (0–18 years) MLL-rearranged |
2014 | Completed |
| NCT02419755 | II | Vorinostat | Histone deacetylases | Relapsed or refractory (0–21 years) MLL-rearranged |
2015 | Completed |
| NCT02420717 | II | Ruxolitinib | JAK1/JAK2 kinases | Ph-like (10 years or older) | 2015 | Completed |
| NCT02723994 | II | Ruxolitinib | JAK1/JAK2 kinases | CRLF2-rearrange and/or JAK pathway-mutant (1–21 years) | 2016 | Recruiting |